drug

Risk status for medication adherence

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
OTHER
Pre-approval / investigational in the US
Developed by Janssen-Cilag Farmaceutica Ltda.
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
OTHER

Indications

Trials

1
Schizophrenia Treatment Adherence Investigation (STAI)
NCT01001481—Completed

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Janssen-Cilag Farmaceutica Ltda.
company
trial
Schizophrenia Treatment Adherence Investigation (STAI)
trial
indication
Schizophrenia
indication
Schizophrenia
indication
Psychotic Disorders
indication
Schizoaffective Disorder
indication